Supervision status and research progress of global abuse of opioids

doi:10.19803/j.1672-8629.20240196

Abstract

Abstract: Objective To sort out the supervision status and research progress of global opioids abuse,and to promote the rational use of drugs and improve the treatment of abusers. Methods The related literature and documents from CNKI, Wanfang Data, PubMed, International Narcotics Control Board, United Nations Office on Drugs and Crime were searched and analysed. Result At present, the situation of global opioids abuse is still not optimistic.International institutions led by the INCB have put forward effective recommendations and launched relevant actions from four dimensions: policy legislation, regional cooperation, production transactions and prevention and treatment. In addition, researchers have also carried out relevant studies from different dimensions, such as related policies, abuse risk prediction, and treatment of abusers. Conclusion Current opioid supervision and research cannot meet the current needs of opioids regulation. In the future, in-depth research is still needed from the aspects of strengthening effective drug regulation, predicting drug abuse risk, improving addiction treatment programs, etc., to further improve the current situation of opioid abuse.

Key words: opioids, drug abuse, supervision measures, rational drug use, abuse risk prediction, research progress

CLC Number:

R954
R971

LI Wenpeng, LIU Mingyu, CAO Ying, ZHOU Huziwei, WANG Shengfeng. Supervision status and research progress of global abuse of opioids[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 513-518.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240196

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I5/513

References

[1] LYDEN J, BINSWANGER IA.The United States Opioid Epidemic[J]. Semin Perinatol, 2019, 43(3): 123-131.
[2] United Nations Office on Drugs and Crime. World Drug Report(2012-2022)[R/OL]. [2024-04-25]. https://www.unodc.org/.
[3] SOLGAMA JP, LIU E, DAVIS M, et al.State-level variation in distribution of oxycodone and opioid-related deaths from 2000 to 2021: an ecological study of ARCOS and CDC WONDER data in the USA[J]. BMJ Open, 2024, 14(3): e073765.
[4] ZHANG L, HUANG XX, LIU KK,et al.Progress on opioid management in China[J]. Anti-Tumor Pharmacy(肿瘤药学), 2023, 13(1): 17-22.
[5] LI ZX, BAO H.Fentanyl material control policy in China: evolution, effectiveness and improvement strategy[J]. Chinese Journal of Drug Abuse Prevention(中国药物滥用防治杂志), 2023, 29(8): 1308-1313.
[6] United Nations Office on Drugs and Crime. Special Conference of the UN General Assembly on World Drugs 2016[R]. United Nations: United Nations Office on Drugs and Crime, 2016.
[7] XU JJ, YAN Y.The US government's regulatory policy on fentanyl[J]. The Journal of Yunnan Police College(云南警官学院学报), 2020(6): 21-29.
[8] International Narcotics Control Board. Progress in ensuring adequate supplies of internationally controlled drugs for medical and scientific purposes[C]. New York: English, Publications and Books, United Nations Office at Vienna, 2019.
[9] ADR, NMPA.US updated instructions for quick and extended release/long-acting opioid analgesics[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(12): 1434.
[10] China Medical Guide.Canada revised opioid instructions to reduce abuse hazards[J]. China Medical Guide(中国医药导刊), 2018, 20(2): 108.
[11] International Narcotics Control Board. Guidelines for Estimating International Controlled Drugs[M]. New York: English, Publications and Books Section, United Nations Office at Vienna, 2012.
[12] International Narcotics Control Board. Report of the International Narcotics Control Board(2019-2023)[R/OL]. [2024-04-25]. https://ecosoc.un.org/en.
[13] DOWELL D, HAEGERICH TM, CHOU R.CDC guideline for prescribing opioids for chronic pain-United States, 2016[J]. Jama, 2016, 315(15): 1624-45.
[14] YANG HL, XU XL, ZHU Z.Overview of US opioid abuse and its governance initiatives[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(12): 746-751.
[15] GELLAD WF, GOOD CB, SHULKIN DJ.Addressing the opioid epidemic in the United States: lessons from the department of veterans Affairs[J]. JAMA Intern Med, 2017, 177(5): 611-112.
[16] International Narcotics Control Board. Supply of internationally controlled drugs: ensure medical and scientific purposes[C]. New York: English, Publications and Books, United Nations Office at Vienna, 2019.
[17] VAN HOUT MC, CROWLEY D, MCBRIDE A, et al.Optimising treatment in opioid dependency in primary care: results from a national key stakeholder and expert focus group in Ireland[J]. BMC Fam Pract, 2018, 19(1): 103.
[18] CLARK JD, JOHNSON M, FABOWALE B, et al. Does the International Narcotics Control Board (INCB) sufficiently prioritise enablement of access to therapeutic opioids? A systematic critical analysis of six INCB annual reports, 1968-2018[J]. Journal of Global Health Reports, 2020:10.29392/001c.12925.
[19] SMART R, GRANT S, GORDON AJ, et al.Expert panel consensus on state-level policies to improve engagement and retention in treatment for opioid use disorder[J]. JAMA Health Forum, 2022, 3(9): E223285.
[20] CHOI S, O'GRADY MA, CLELAND CM, et al. Clinics optimizing methadone take-homes for opioid use disorder(COMET): protocol for a stepped-wedge randomized trial to facilitate clinic level changes[J]. PLoS ONE, 2023, 18(6): pone.0286859.
[21] PANWALA V, THORN E, AMIRI S, et al.Opioid use and COVID-19: a secondary analysis of the impact of relaxation of methadone take-home dosing guidelines on use of illicit opioids[J]. Am J Drug Alcohol Abuse, 2023, 49(5): 597-605.
[22] OVIEDO-JOEKES E, DOBISCHOK S, CARVAJAL J, et al.Clients' experiences on North America's first take-home injectable opioid agonist treatment(iOAT) program: a qualitative study[J]. BMC Health Serv Res, 2023, 23(1): 553.
[23] ADAMS A, BLAWATT S, MACDONALD S, et al.Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: a qualitative systematic review[J]. Int J Drug Policy, 2023, 117: 104058.
[24] SHOJAATI N, OSGOOD ND.Evaluating the Impact of increased dispensing of opioid agonist therapy take-home doses on treatment retention and opioid-related harm among opioid agonist therapy recipients: a simulation study[J]. Systems, 2023, 11(8): 391.
[25] MAGEL T, MATZINGER E, BLAWATT S, et al.How injectable opioid agonist treatment (iOAT) care could be improved? service providers and stakeholders'perspectives[J]. Drugs Educ Prev Policy, 2024, 31(2): 200-211.
[26] WEINER SG, PRICE CN, ATALAY AJ, et al.A Health system-wide initiative to decrease opioid-related morbidity and mortality[J]. Jt Comm J Qual Patient Saf, 2019, 45(1): 3-13.
[27] BANDARA S, MANIATES H, HULSEY E, et al.Opioid treatment program safety measures during the COVID-19 pandemic: a statewide survey[J]. BMC Health Serv Res, 2022, 22(1): 1-9.
[28] FRUEH L, COLLINS AB, NEWMAN R, et al.Multi-level influences on increased overdose risk behaviors during the COVID-19 pandemic among people who use drugs in Rhode Island: a qualitative investigation[J]. Harm Reduct J, 2023, 20(1): 14.
[29] LEVENTELIS C, KATSOULI A, STAVROPOULOS V, et al.The development and validation of the pandemic medication-assisted treatment questionnaire for the assessment of pandemic crises impact on medication management and administration for patients with opioid use disorders[J]. NAT Nord Stud Alcohol Drugs, 2023, 40(1): 76-94.
[30] JUDD D, KING CR, GALKE C.The opioid epidemic: a review of the contributing factors, negative consequences, and best practices[J]. Cureus, 2023, 15(7): e41621.
[31] BEDENE A, DAHAN A, ROSENDAAL FR, et al.Opioid epidemic: lessons learned and updated recommendations for misuse involving prescription versus non-prescription opioids[J]. Expert Rev Clin Pharmacol, 2022, 15(9): 1081-1094.
[32] ZHANG M, LIU W.Risk assessment and management of opioid abuse in patients with cancer pain[J]. Medical guide(医药导报), 2021, 40(1): 51-55.
[33] BUTLER C, MMONU N, COHEN AJ, et al.Pre-operative assessment tool to predict post-operative pain and opioid use in outpatient urologic surgery[J]. Urology, 2022, 161: 19-24.
[34] STALTER N, MA S, SIMON G, et al.Psychosocial problems and high amount of opioid administration are associated with opioid dependence and abuse after first exposure for chronic pain patients[J]. Addict Behav, 2023, 141: 107657.
[35] CHEATLE MD, COMPTON PA, DHINGRA L, et al.Development of the revised opioid risk tool to predict opioid use disorder in patients with chronic nonmalignant pain[J]. J Pain, 2019, 20(7): 842-851.
[36] DEREFINKO KJ, SALGADO GFI, TALLEY KM, et al.Adverse childhood experiences predict opioid relapse during treatment among rural adults[J]. Addict Behav, 2019, 96: 171-174.
[37] COLOMA-CARMONA A, CARBALLO JL, RODRÍGUEZ-MARÍN J, et al. Withdrawal symptoms predict prescription opioid dependence in chronic pain patients[J]. Drug Alcohol Depend, 2019, 195: 27-32.
[38] HASTINGS JS, HOWISON M, INMAN SE.Predicting high-risk opioid prescriptions before they are given[J]. Proc Natl Acad Sci USA, 2020, 117(4): 1917-1923.
[39] LU Y, FORLENZA E, WILBUR RR, et al.Machine-learning model successfully predicts patients at risk for prolonged postoperative opioid use following elective knee arthroscopy[J]. Knee Surg Sports Traumatol Arthrosc, 2022, 30(3): 762-772.
[40] SINGH K, MURALI A, STEVENS H, et al.Predicting persistent opioid use after surgery using electronic health record and patient-reported data[J]. Surgery, 2022, 172(1): 241-248.
[41] WILSON M, ODOM-MARYON T, STANEK K, et al.Hyperbaric oxygen to assist adults with opioid use disorder in reducing methadone dose[J]. J Addict Nurs, 2022, 33(1): 27-36.
[42] SRIVASTAVA A, CLARKE S, HARDY K, et al.Facilitating rapid access to addiction treatment: a randomized controlled trial[J]. Addict Sci Clin Pract, 2021, 16(1): 34.
[43] REIF DE PAULA T, NEMETH SK, KURLANSKY PA, et al. A randomized controlled trial examining the impact of an anorectal surgery multimodal enhanced recovery program on opioid use[J]. Ann Surg, 2022, 275(1): e22-e29.
[44] SHIRK SD, AMERAL V, KRAUS SW, et al.Buprenorphine naloxone and extended release injectable naltrexone for the treatment of opioid use disorder among a veteran patient sample: a retrospective chart review[J]. J Dual Diagn, 2021, 17(3): 207-215.
[45] OLIVETO AH, FEINGOLD A, SCHOTTENFELD R, et al.Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone[J]. Arch Gen Psychiatry, 1999, 56(9): 812-820.
[46] BUSCH SH, FIELLIN DA, CHAWARSKI MC, et al.Cost-effectiveness of emergency department-initiated treatment for opioid dependence[J]. Addiction, 2017, 112(11): 2002-2010.
[47] JUTRAS-ASWAD D, LE FOLL B, AHAMAD K, et al.Flexible buprenorphine/naloxone model of care for reducing opioid use in individuals with prescription-type opioid use disorder: an open-label, pragmatic, noninferiority randomized controlled trial[J]. Am J Psychiatry, 2022, 179(10): 726-739.
[48] NOVAK MD, HOLTYN AF, TOEGEL F, et al.Abstinence-contingent wage supplements to promote drug abstinence and employment: post-intervention outcomes[J]. Drug Alcohol Depend, 2022, 232: 109322.
[49] PSARIANOS A, CHRYSSANTHOPOULOS C, PAPARRIGOPOULOS T, et al.The role of physical exercise in opioid substitution therapy: mechanisms of sequential effects[J]. Int J Mol Sci, 2023, 24(5): 4763.
[50] DONG Y, DAI SH, DONG YG, et al.Intervention effects of exercise on the harm of opioid abuse[J]. China Sports Science and Technology(中国体育科技), 2023, 59(9): 54-62.
[51] JONES K F, O'REILLY JM, SPETZ J, et al. Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach[J]. J Nurs Scholarsh, 2023, 55(3): 655-664.
[52] KIM J, LEE J, THORNHILL TA, et al.Accessibility of opioid treatment programs based on conventional vs perceived travel time measures[J]. JAMA Netw Open, 2024, 7(2): e240209.
[53] MADDEN EF, BARKER KK, GUERRA J, et al.Variation in intervention stigma among medications for opioid use disorder[J]. SSM, 2022, 2: 100161.
[54] DONG ZM, ZENG SY, QUE X.Introduction of opioid abuse prevention technology[J]. Science & Technology Vision(科技视界), 2022(34): 36-41.